9 Meters Biopharma, Inc.
NMTRQ
$0.00
$0.000.00%
03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
---|---|---|---|---|---|
Net Income | -8.39% | -19.00% | -28.60% | -68.93% | 32.57% |
Total Depreciation and Amortization | 2.50% | 13.33% | 43.55% | -28.33% | -44.06% |
Total Amortization of Deferred Charges | -- | 4,062.95% | 37.17% | -100.00% | -100.00% |
Total Other Non-Cash Items | -13.80% | -19.83% | -9.85% | 280.82% | -86.38% |
Change in Net Operating Assets | -53.21% | -70.38% | 277.81% | 583.79% | 340.27% |
Cash from Operations | -12.86% | -26.34% | -27.03% | -40.84% | -43.47% |
Capital Expenditure | 100.00% | 77.60% | 45.45% | -21.74% | -37.33% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | 100.00% | -- | 24.06% |
Cash from Investing | 100.00% | 99.88% | 99.78% | -35,066.67% | 23.92% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | 100.00% | 100.00% | 100.00% |
Issuance of Common Stock | -86.51% | -- | -98.26% | -97.78% | -20.45% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 43.95% | 62.49% | 79.60% | 95.15% | 52.42% |
Cash from Financing | -77.69% | -51.49% | -70.26% | -97.93% | -44.90% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -2,261.92% | -289.61% | -134.52% | -168.38% | -103.50% |